scholarly journals Core Data Elements in Acute Myeloid Leukemia: A Unified Medical Language System–Based Semantic Analysis and Experts’ Review (Preprint)

2019 ◽  
Author(s):  
Christian Holz ◽  
Torsten Kessler ◽  
Martin Dugas ◽  
Julian Varghese
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Data ◽  
Myeloid Leukemia ◽  
Data Capture ◽  
Large Set ◽  
Unified Medical Language System ◽  
Medical Language ◽  
Data Elements ◽  
Medical Concepts ◽  
Acute Myeloid

BACKGROUND For cancer domains such as acute myeloid leukemia (AML), a large set of data elements is obtained from different institutions with heterogeneous data definitions within one patient course. The lack of clinical data harmonization impedes cross-institutional electronic data exchange and future meta-analyses. OBJECTIVE This study aimed to identify and harmonize a semantic core of common data elements (CDEs) in clinical routine and research documentation, based on a systematic metadata analysis of existing documentation models. METHODS Lists of relevant data items were collected and reviewed by hematologists from two university hospitals regarding routine documentation and several case report forms of clinical trials for AML. In addition, existing registries and international recommendations were included. Data items were coded to medical concepts via the Unified Medical Language System (UMLS) by a physician and reviewed by another physician. On the basis of the coded concepts, the data sources were analyzed for concept overlaps and identification of most frequent concepts. The most frequent concepts were then implemented as data elements in the standardized format of the Operational Data Model by the Clinical Data Interchange Standards Consortium. RESULTS A total of 3265 medical concepts were identified, of which 1414 were unique. Among the 1414 unique medical concepts, the 50 most frequent ones cover 26.98% of all concept occurrences within the collected AML documentation. The top 100 concepts represent 39.48% of all concepts’ occurrences. Implementation of CDEs is available on a European research infrastructure and can be downloaded in different formats for reuse in different electronic data capture systems. CONCLUSIONS Information management is a complex process for research-intense disease entities as AML that is associated with a large set of lab-based diagnostics and different treatment options. Our systematic UMLS-based analysis revealed the existence of a core data set and an exemplary reusable implementation for harmonized data capture is available on an established metadata repository.

scholarly journals Core Data Elements in Acute Myeloid Leukemia: A Unified Medical Language System–Based Semantic Analysis and Experts’ Review

10.2196/13554 ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. e13554 ◽  
Author(s):  
Christian Holz ◽  
Torsten Kessler ◽  
Martin Dugas ◽  
Julian Varghese
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Data ◽  
Myeloid Leukemia ◽  
Data Capture ◽  
Large Set ◽  
Unified Medical Language System ◽  
Medical Language ◽  
Data Elements ◽  
Medical Concepts ◽  
Acute Myeloid

Background For cancer domains such as acute myeloid leukemia (AML), a large set of data elements is obtained from different institutions with heterogeneous data definitions within one patient course. The lack of clinical data harmonization impedes cross-institutional electronic data exchange and future meta-analyses. Objective This study aimed to identify and harmonize a semantic core of common data elements (CDEs) in clinical routine and research documentation, based on a systematic metadata analysis of existing documentation models. Methods Lists of relevant data items were collected and reviewed by hematologists from two university hospitals regarding routine documentation and several case report forms of clinical trials for AML. In addition, existing registries and international recommendations were included. Data items were coded to medical concepts via the Unified Medical Language System (UMLS) by a physician and reviewed by another physician. On the basis of the coded concepts, the data sources were analyzed for concept overlaps and identification of most frequent concepts. The most frequent concepts were then implemented as data elements in the standardized format of the Operational Data Model by the Clinical Data Interchange Standards Consortium. Results A total of 3265 medical concepts were identified, of which 1414 were unique. Among the 1414 unique medical concepts, the 50 most frequent ones cover 26.98% of all concept occurrences within the collected AML documentation. The top 100 concepts represent 39.48% of all concepts’ occurrences. Implementation of CDEs is available on a European research infrastructure and can be downloaded in different formats for reuse in different electronic data capture systems. Conclusions Information management is a complex process for research-intense disease entities as AML that is associated with a large set of lab-based diagnostics and different treatment options. Our systematic UMLS-based analysis revealed the existence of a core data set and an exemplary reusable implementation for harmonized data capture is available on an established metadata repository.

scholarly journals Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Blood ◽  
2012 ◽  
Vol 119 (26) ◽  
pp. 6198-6208 ◽  
Author(s):  
Roland B. Walter ◽  
Frederick R. Appelbaum ◽  
Elihu H. Estey ◽  
Irwin D. Bernstein
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Clinical Data ◽  
Myeloid Leukemia ◽  
Gemtuzumab Ozogamicin ◽  
Promyelocytic Leukemia ◽  
Differentiation Antigen ◽  
Conventional Chemotherapy ◽  
Mechanistic Basis ◽  
Acute Myeloid

Although the identification of cancer stem cells as therapeutic targets is now actively being pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia (AML) are a paradigm of such a strategy. Heterogeneity of these cells was suggested by clonal analyses indicating the existence of both leukemias resulting from transformed multipotent CD33− stem cells as well others arising from, or predominantly involving, committed CD33+ myeloid precursors. The latter leukemias, which may be associated with an intrinsically better prognosis, offer a particularly attractive target for stem cell-directed therapies. Targeting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an approach. Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute promyelocytic leukemia but, in combination with conventional chemotherapy, also for other favorable- and intermediate-risk AMLs, providing the first proof-of-principle evidence for the validity of this strategy. Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and failure in various AML subsets.

scholarly journals High expression of AFFs is related to prognosis of acute myeloid leukemia

2021 ◽  
Author(s):  
xi chen ◽  
Qin Yan ◽  
Xiang Qin ◽  
Jing Liu ◽  
Yan Zeng ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Mrna Expression ◽  
Real Time ◽  
Quantitative Pcr ◽  
Clinical Data ◽  
Myeloid Leukemia ◽  
Functional Enrichment ◽  
High Expression ◽  
The Relationship ◽  
Acute Myeloid

Abstract BackgroundAFF family genes (AFF1, AFF2, AFF3, AFF4, AFFs) are closely related to the occurrence, development and prognosis of a variety of tumors, but the relationship between AFFs and acute myeloid leukemia (AML) is still unclear. This study aims to explore the relationship between AFFs and the prognosis of AML by bioinformatics and real time quantitative PCR. MethodsAnalyze the expression of AFFs in AML patients and AML cell lines through ONCOMINE, GEPIA, EMBL-EBI, and CCLE databases, explore the prognostic value of AFFs in AML through the TCGA database,explore Co-expression and functional enrichment analysis of AFFs through the Linkedomics, DAVID and KOBAS database.We collected peripheral blood samples of 24 cases of AML (non-M3 subtype) and 8 cases of benign individuals, and detected the mRNA expression level of AFFs by real-time fluorescent quantitative PCR (clinical data comes from hospitalized medical records). ResultsThe results of multiple data sets showed that the mRNA transcription level of AFF1, AFF2, AFF3, and AFF4 in AML was significantly higher than that of normal people. Among them, the high expression of AFF1, AFF2, and AFF3 was statistically significant (p<0.05). Our clinical data showed that the mRNA expression levels of AFF1 and AFF2 in AML patients were higher than those in the control group (p<0.05). The high expression of AFF1 was significantly negatively correlated with overall survival (OS) (p<0.05), the high expression of AFF2 was significantly positively correlated with OS (p<0.05), and the high expression of AFF3 was not correlated with OS (p>0.05). ConclusionAFF1 and AFF2 are highly expressed in AML. The high expression of AFF1 is significantly negatively correlated with OS, and the high expression of AFF2 is significantly positively correlated with OS, which may become a new target for treatment.

scholarly journals Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia

2017 ◽  
Vol 5 (1) ◽  
pp. 232470961769074 ◽  
Author(s):  
Mayur D. Mody ◽  
Deepak Ravindranathan ◽  
Harpaul S. Gill ◽  
Vamsi K. Kota
Keyword(s):  
Acute Myeloid Leukemia ◽  
Side Effects ◽  
High Risk ◽  
Acute Leukemia ◽  
Drug Interactions ◽  
Clinical Data ◽  
Myeloid Leukemia ◽  
Antifungal Prophylaxis ◽  
Relapsed Acute Myeloid Leukemia ◽  
Acute Myeloid

Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.

Sign in / Sign up

Export Citation Format

Share Document